Enhertu's Inclusion in China's State Insurance: A Milestone in Cancer Treatment Accessibility
Share
Introduction
AstraZeneca's breast cancer drug, Enhertu, co-developed with Japan's Daiichi Sankyo, has been added to China's national health insurance scheme, effective January 1. This inclusion aims to enhance public accessibility to this innovative treatment within a country of 1.4 billion people. Enhertu targets HER-2 positive breast cancer patients and is recognized for delivering toxic chemotherapy directly to tumors.
The Impact of This Decision
China's decision to include Enhertu in its state insurance scheme reflects a growing commitment to improving public access to innovative treatments. While this move will likely lead to price reductions for the drug, it is expected to expand its reach across China’s vast population. For AstraZeneca, this decision strengthens its foothold in one of the world’s largest pharmaceutical markets, which accounts for 13% of its global revenue.
How Clinicians Check Helps
As access to innovative treatments like Enhertu increases, so does the need for accurate information about their real-world efficacy and side effects. Clinicians Check provides a platform where healthcare providers can share their clinical experiences with such drugs, offering valuable insights into their performance outside controlled trials. Patients can also access reviews to understand what to expect, empowering them to make informed decisions.
Source: